cisapride has been researched along with Cystic Fibrosis in 17 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, placebo-controlled, crossover trial, we investigated the effects of the prokinetic drug cisapride in patients with cystic fibrosis and chronic recurrent distal intestinal obstruction syndrome (DIOS)." | 9.06 | Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. ( Corey, M; Durie, PR; Ellis, L; Koletzko, S; Spino, M; Stringer, DA, 1990) |
| "When cisapride was given, there was frequent irregular contractile activity, faster gastric emptying, and no symptoms of lethargy." | 5.27 | Absent postprandial duodenal motility in a child with cystic fibrosis. Correction of the symptoms and manometric abnormality with cisapride. ( Hyman, PE, 1986) |
| "In a double-blind, placebo-controlled, crossover trial, we investigated the effects of the prokinetic drug cisapride in patients with cystic fibrosis and chronic recurrent distal intestinal obstruction syndrome (DIOS)." | 5.06 | Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. ( Corey, M; Durie, PR; Ellis, L; Koletzko, S; Spino, M; Stringer, DA, 1990) |
| "This paper provides a comprehensive review of the current knowledge on cisapride in different clinical conditions in children: different manifestations of gastro-oesophageal reflux, such as (excessive) regurgitation, oesophagitis, chronic respiratory disease or uncontrolled asthma, cystic fibrosis, chronic dyspepsia, constipation and pseudo-obstruction, and as an aid to small bowel capsule-biopsy." | 4.80 | Clinical use of cisapride and its risk-benefit in paediatric patients. ( Vandenplas, Y, 1998) |
| "Gastroesophageal reflux (GER) may aggravate chronic bronchopulmonary diseases." | 1.31 | Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. ( Brodzicki, J; Korzon, M; Trawińska-Bartnicka, M, 2002) |
| "Weight gain was significant and recurrent cough and wheeze disappeared." | 1.28 | New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. ( Dab, I; Malfroot, A, 1991) |
| "Abnormal degrees of gastro-oesophageal reflux (GOR) were detected by 24 hour intraoesophageal pH measurement in 12 of 14 children (mean age 7." | 1.28 | Mechanisms of gastro-oesophageal reflux in cystic fibrosis. ( Andreotti, MR; Cucchiara, S; de Ritis, G; Ercolini, P; Minella, R; Oggero, V; Santamaria, F, 1991) |
| "When cisapride was given, there was frequent irregular contractile activity, faster gastric emptying, and no symptoms of lethargy." | 1.27 | Absent postprandial duodenal motility in a child with cystic fibrosis. Correction of the symptoms and manometric abnormality with cisapride. ( Hyman, PE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, W | 2 |
| Green, J | 2 |
| Gilchrist, FJ | 2 |
| Brodzicki, J | 1 |
| Trawińska-Bartnicka, M | 1 |
| Korzon, M | 1 |
| Schäppi, MG | 1 |
| Roulet, M | 1 |
| Rochat, T | 1 |
| Belli, DC | 1 |
| Jones, R | 1 |
| Franklin, K | 1 |
| Spicer, R | 1 |
| Berry, J | 1 |
| Cucchiara, S | 2 |
| Raia, V | 2 |
| Minella, R | 2 |
| Frezza, T | 1 |
| De Vizia, B | 1 |
| De Ritis, G | 3 |
| Vandenplas, Y | 1 |
| Bosheva, M | 1 |
| Ivancheva, D | 1 |
| Genkova, N | 1 |
| Lutzkanova, Z | 1 |
| Klinkanova, M | 1 |
| Malfroot, A | 2 |
| Dab, I | 2 |
| Santamaria, F | 2 |
| Andreotti, MR | 1 |
| Ercolini, P | 1 |
| Oggero, V | 2 |
| Koletzko, S | 1 |
| Corey, M | 1 |
| Ellis, L | 1 |
| Spino, M | 1 |
| Stringer, DA | 1 |
| Durie, PR | 1 |
| Smith, HL | 1 |
| Handy, DJ | 1 |
| Weller, PH | 1 |
| Booth, IW | 1 |
| Salvatore, D | 1 |
| Vittoria, L | 1 |
| Prinsen, JE | 1 |
| Thomas, M | 1 |
| Hyman, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit[NCT04210427] | Phase 4 | 3 participants (Actual) | Interventional | 2019-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cisapride and Cystic Fibrosis
| Article | Year |
|---|---|
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Topics: Cisapride; Constipation; Cystic Fibrosis; Humans; Intestinal Obstruction; Quality of Life; Randomize | 2021 |
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Topics: Adolescent; Adult; Cisapride; Cystic Fibrosis; Gastrointestinal Agents; Humans; Intestinal Obstructi | 2018 |
Clinical use of cisapride and its risk-benefit in paediatric patients.
Topics: Child; Child, Preschool; Cisapride; Constipation; Cystic Fibrosis; Drug Interactions; Dyspepsia; Fec | 1998 |
4 trials available for cisapride and Cystic Fibrosis
| Article | Year |
|---|---|
Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Dyspepsia; Female; Gastric Emptying | 1996 |
Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome.
Topics: Adolescent; Adult; Chronic Disease; Cisapride; Cystic Fibrosis; Double-Blind Method; Female; Humans; | 1990 |
Cisapride and cystic fibrosis.
Topics: Adolescent; Child; Cisapride; Clinical Trials as Topic; Cystic Fibrosis; Double-Blind Method; Female | 1989 |
Cisapride in cystic fibrosis.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Clinical Trials as Topic; Cystic Fibrosis; Double-Bl | 1985 |
10 other studies available for cisapride and Cystic Fibrosis
| Article | Year |
|---|---|
Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Endoscopy | 2002 |
Electrogastrography reveals post-prandial gastric dysmotility in children with cystic fibrosis.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Electrophysio | 2004 |
Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes.
Topics: Alginates; Aluminum Hydroxide; Amylases; Antacids; Anti-Ulcer Agents; Bromelains; Cisapride; Colon; | 1995 |
FDA approved. New drug bulletin: Cisapride and Dornase alfa.
Topics: Adult; Anti-Ulcer Agents; Child; Cisapride; Cystic Fibrosis; Deoxyribonuclease I; Drug Interactions; | 1994 |
Gastroesophageal reflux in children with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Female; Gastroesophageal Ref | 1998 |
New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up.
Topics: Child, Preschool; Cisapride; Cough; Cystic Fibrosis; Female; Follow-Up Studies; Gastroesophageal Ref | 1991 |
Mechanisms of gastro-oesophageal reflux in cystic fibrosis.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Drainage, Postural; Esophagogastric | 1991 |
Cisapride and cystic fibrosis.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Double-Blind Method; Female; Humans | 1989 |
Absent postprandial duodenal motility in a child with cystic fibrosis. Correction of the symptoms and manometric abnormality with cisapride.
Topics: Bethanechol; Bethanechol Compounds; Cisapride; Cystic Fibrosis; Duodenal Obstruction; Duodenum; Esop | 1986 |
Gastroesophageal reflux: a primary defect in cystic fibrosis?
Topics: Child, Preschool; Cisapride; Cystic Fibrosis; Female; Follow-Up Studies; Gastroesophageal Reflux; Hu | 1988 |